Radioactive isotopes of rare earth elements have effective nuclear-physical properties and are promising for the development of new therapeutic radiopharmaceuticals. Rare earth elements (REE) include 17 elements of the secondary subgroup of group III of the periodic table of chemical elements of D.I. Mendeleev with atomic numbers 21, 39, 57, 58–71: scandium, yttrium, lanthanum and 14 lanthanides. Some radioactive isotopes of these elements are already used in medicine, as a radioactive component of approved medicines, for example, the isotopes of ¹⁵³Sm and ¹⁷⁷Lu, and for some the possibility of their use in medicine is only being studied. Thus, the isotope scandium – ⁴⁷Sc is being studied as a potential radioisotope for cancer diagnosis, holmium – ¹⁶⁶Ho as an isotope for radiosynovectomy and brachytherapy, praseodymium – ¹⁴²Pr is promising for brachytherapy. The ability of rare earth elements to form chemical bonds with organic molecules, including peptides of natural and synthetic origin, is the basis for the development of new drugs for targeted therapy of breast and prostate cancer, neuroendocrine tumors, disseminated lung cancer and other types of diseases. To determine the list of the most promising for irradiation at the rector of the WWR-K REE in order to develop radioactive isotopes, an assessment of the ways of developing radioactive isotopes and an analysis of their nuclear physical characteristics according to literature data was carried out. Isotopes such as: ¹⁶⁶Ho, ¹⁶⁵Dy, ⁹⁰Y, ¹⁷⁵Yb, ¹⁵³Sm, ¹⁷⁷Lu, ¹⁴⁷Nd, ¹⁷⁰Tm, ¹⁵⁹Gd and ¹⁴¹Ce can be used in the treatment of oncological diseases. This research work makes it possible to evaluate the possibility of obtaining REE radioisotopes by reaction (n, γ) at the WWR-K reactor, and reflects the prospects for using these isotopes in the development of new-generation radiopharmaceuticals for the treatment of oncological diseases.

This paper presents the development of a method for the regeneration of molybdenum‐98 from spent ⁹⁹ Mo/ ^99m Tc generators for its reuse in the technological cycle. An optimal process for the regeneration of molybdenum from industrial waste is proposed, in which the loss rate of molybdenum is no more than 5%. Original methods and a schematic diagram of the regeneration processes are created. This study shows the possibility of using regenerated molybdenum‐98 in the manufacturing technology of technetium generators. This is confirmed by the quality of the eluate from the generator made based on the regenerated product, which, in all respects, meets the requirements of regulatory documentation. The development of molybdenum regeneration technology emphasises creating techniques that include a minimum number of stages with minimal amounts of materials used.

Background: Gastric cancer remains a leading cause of cancer‐related morbidity and mortality worldwide, and accurate imaging is critical for diagnosis, staging, recurrence detection, and prognostic assessment. Positron emission tomography (PET), traditionally performed using ¹⁸ F‐fluorodeoxyglucose (FDG), has demonstrated variable performance in gastric cancer, particularly for nodal and peritoneal disease. Recently, ⁶⁸ Ga‐labeled fibroblast activation protein inhibitor (FAPI) PET has emerged as a promising alternative, prompting multiple systematic reviews and meta‐analyses with heterogeneous findings. Objective: We are aimed at synthesizing and appraise meta‐analytic evidence on PET imaging in gastric cancer, with a focus on radiopharmaceutical‐specific performance by clinical indication and certainty of evidence to inform personalized tracer selection. Methods: An umbrella review was conducted in accordance with PRISMA 2020. The protocol was prospectively registered in the Open Science Framework (OSF). PubMed, Scopus, and Web of Science were searched from inception to December 2025 for systematic reviews and meta‐analyses evaluating PET imaging in gastric cancer. Outcomes included diagnostic accuracy, staging and restaging performance, recurrence detection, prognostic associations, methodological quality (AMSTAR‐2), and certainty of evidence (GRADE). Results: Eleven meta‐analyses published between 2011 and 2025 were included. FDG PET/CT demonstrated moderate diagnostic performance overall, with high specificity but limited sensitivity for lymph node and peritoneal metastases, while retaining moderate certainty for prognostic assessment based on standardized uptake value (SUV)–derived metrics. In contrast, ⁶⁸ Ga‐FAPI PET generally showed higher pooled sensitivity than FDG for primary tumor detection, nodal disease, peritoneal metastases, and recurrence detection across available meta‐analyses, although the certainty of evidence ranged from low to moderate and some findings were derived from mixed‐population reviews. Conclusions: Available meta‐analytic evidence suggests an indication‐driven, personalized approach to PET imaging in gastric cancer. FDG PET remains useful for prognostic stratification and selected recurrence settings, whereas FAPI PET appears to offer higher diagnostic sensitivity for staging and restaging, particularly for peritoneal disease. Nevertheless, the overall certainty of evidence remains limited by heterogeneity, indirectness, and the absence of updated de novo pooled analyses.

This article provides a brief overview of the 18F isotope production using the Cyclone-30 cyclotron and two liquid targets with the volume of 0.5 and 2.0 ml, water enriched with the 18O isotope was used as the target material. The obtained isotope was used for serial production of the [18F]FDG radiopharmaceutical and supply of this medicine to the operating PET centers in Almaty. The isotope was also used for experimental syntheses of [18F]PSMA-1007 and Na[18F]F to assess the possibility of implementation these medicines into the production and medical practice of the Republic of Kazakhstan. The need for the implementation of [18F]PSMA-1007 is associated with the problem of early diagnosis and control of prostate cancer treatment, and Na[18F]F - with the earliest possible detection of bone metastases in malignant tumors of various localization. This paper provides the average radiochemical yield and the main quality parameters for [18F]FDG, [18F]PSMA-1007 and Na[18F]F. This scientific and practical work allows us to evaluate the three-year production experience and the possibilities of fluorine production by reaction (p,n) on the cyclotron С-30, and also reflects the prospects of using fluorine in the development of new-generation radiopharmaceuticals for the diagnosis of oncological diseases.